Lynn is a biotech entrepreneur and the founder of STALICLA. Driven by her lifelong involvement with the autism patient and research community, she co-developed the Databased Endophenotyping Patient Identification model to kick-start systems biology-based drug development in ASD. Lynn has extensive experience in Business Development and has previously worked for the World Economic Forum, a leading Swiss venture capital firm, and startup accelerators in the lemanic area. She has also spent 5 years at the Faculty of Medicine at the University of Geneva. Lynn Durham holds a master degree in political sciences and economic history and another in corporate communication. Lynn is finalizing a post-graduate degree in Drug Discovery and clinical Development at the Faculty of medicine of the University of Geneva.
Jean-Marc is a scientist in cellular and molecular biology, and project manager with ten years of experience in academic research laboratories and eight years in pharmaceutical companies. He has been instrumental in directing and improving processes, enhancing productivity, and implementing technology solutions in various drug/medtech development projects. He is skilled in spearheading research and innovation activity in corporate settings and has a strong ability to develop and maintain partnerships.
Joseph has 20 years' experience in drug discovery on the R&D interface. He has held various leading positions in the industry as former Head of Psychiatry Disease area and Vice President, Neurosciences, at Roche. Prior to that, he held the positions of Director, Systems Pharmacology CNS Research at SANOFI and ITEM Scientific Director.
Luigi is a research scientist and clinical geneticist at the Greenwood Genetic Center (GGC). His research focuses on autism spectrum disorder, intellectual disability and overgrowth conditions. He holds a position as Assistant Professor at the Clemson University School of Health Research. He works around the definition of metabolomics profiles applied to several genetic conditions with a special focus on pathogenic mechanisms and molecular biomarkers identification, as well as novel treatment strategies development.
Xavier is a Neuropsychologist by training with 18 years’ experience in clinical drug development. Before joining STALICLA, Xavier spent 18 years at Roche, including 8 years in the Neuroscience Translational Medicine group. Xavier developed a strong expertise in the Intellectual Disability field as a Senior Principal Scientist for projects in Down syndrome and Autism. He worked closely with the Autism consortia and was an active member of NIMH working groups to identify suitable clinical endpoints for trials in Down syndrome and to foster drug development in Neurodevelopmental Disorders.
Adriano holds a master degree in Pharmacology and a Ph.D. in Immunology. He has 10 years’ experience in drug discovery running target validation and efficacy studies, particularly those related to autoimmune and neurological diseases. He performed pre-clinical pharmacological screening and extensive benchmarking of investigational drugs at the Merck/EMD Serono research sites in Geneva and Great Boston. He managed discovery project teams in industry and collaborations of therapeutic interest between Pharma/Academia. Having more recently worked as a site manager during a Phase III trial for a vaccine against Dengue Fever, he also gained experience in a clinical development setting.
Dr. Kaufmann was a member of the DSM-5 Autism committee. Former Professor of Neurology at Harvard Medical School and a Simons Investigator at Massachusetts Institute of Technology’s Simons Center for the Social Brain. His research uses a multidisciplinary approach to understanding the basis of cognitive and behavioral problems in children with genetic disorders associated with intellectual disability and autism spectrum disorder, with an emphasis on developing new therapeutic interventions.
Julien obtained his medical degree from the University of Lausanne. His strong interest in research rapidly led him to do a MSc in Oncology at the University of Nottingham and a PhD in Biochemistry at the University of Geneva gaining authorship in 8 peer-reviewed publications. Julien has transferred to industry driven by his strong interest in patient focused innovation and translational medicine.
Kirstie has nine years’ experience working for leading entrepreneurs internationally in Melbourne, London and Geneva. She is responsible for administrative coordination, liaising with external accounting offices and statutory auditors.
Expanding from its original DEPI model, STALICLA is scaling up its in-silico R&D effort to further identify new personalized medicine candidates for patients with ASD and has established a dedicated systems biology unit in Barcelona, Spain. The research and development unit of STALICLA in Spain aims to further identify subgroups of patients based on genetic, phenotypic and clinical factors, integrating molecular, anatomical and medical data. Through big data analysis, the project aims to exploit the characteristics of patients in each subgroup to reuse drugs that are already on the market or in the advanced stages of clinical trials. Computational analysis of omics data (proteomics, genomics, transcriptomics, metabolomics, etc.) and personalized systems medicine approaches are at the core of the team’s effort to identify new candidates to expand STALICLA’s pipeline. Core technics supporting this analysis involves statistical modeling and machine learning centered on the biology of diseases, comorbidities and pharmacology.